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ABSTRACT 
Objective: Present investigation was undertaken to know the prevalence of extended spectrum beta-lactamases (ESBLs) among the collected 
isolates and to analyse the antibiotic susceptibility patterns of cefepime/sulbactam, cefepime/tazobactam, imipenem/cilastatin and cefepime 
against these isolates. 
Methods: A total of 1259 clinical samples were collected from patients suspected of bacterial infection between July 2013 to July 2014. These 
samples were subjected for bacterial identification. The prevalence of ESBLs among these isolates and antibiotic susceptibility testing were carried 
out according to the recommendations of Clinical Laboratory Standards Institute (CLSI) guidelines (2013). 
Results: Out of the samples analyzed, 64.3% (810/1259) samples showed the growth of organisms in the culture medium. Of the 810 organisms, 
72.7% (589/810) were ESBL positive. Majority of ESBL producing organisms were obtained from urine (32.2 %) followed by blood (28.5 %), swab 
(12.7%) and sputum (11.3 %). Pus, Bile and fluid samples samples contributed to 8.1 %, 4.0 %, and 3.0% respectively. The organisms that identified 
were E. coli (n=255), P. aeruginosa (208), Klebsiella spp. (81), A. baumannii (32), and H. Influenzae (13). Among all drugs tested, cefepime plus 
sulbactam (Supime) revealed the highest activity against ESBL producing Gram negative organisms. The susceptibility of cefepime plus sulbactam 
against E. coli, P. aeruginosa, K. pneumoniae, A. baumannii, and H. influenzae was 89.9%, 84.6%, 85%, 90.4% and 100%, respectively which was high 
compared to cefepime, cefepime plus tazobactam and imipenem plus cilastatin.  
Conclusion: Overall, the results of the present study strongly advocate the superiority of cefepime/sulbactam over cefepime/tazobactam, 
imipenem/cilastatin and cefepime and can be of very effective alternative to treat against the deadly multidrug resistant Gram negative bacteria. 
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INTRODUCTION 
Broad-spectrum cephalosporins are the mainstay in the treatment of 
various human diseases, such as pneumonia, skin and tissue 
infections, pelvic inflammatory disease, and other conditions caused 
by Gram-negative organisms. Cefepime, a fourth generation 
cephalosporin that has a broader spectrum of activity against Gram 
negative organisms than other extended-spectrum cephalosporins 
and also has potential action against Gram positive cocci, such as 
staphylococcal and streptococcal species [1].  
A broad and potent spectrum of activity together with its advanced 
pharmacological properties makes cefepime a suitable choice of 
antibiotic for initial empirical therapy for febrile neutropenic 
patients [1]. The effectiveness of cefepime has been demonstrated 
by several studies, either alone or in combination [2-4]. 
However, extensive long term clinical usage lead to the emergence of 
resistance against this antimicrobial agent [5, 6]. A study done by 
Jazani et al. [7] in which they showed resistance rate of cefepime 
against P. aeruginosa was 75.4%, whereas Satti et al. [8] reported 
that resistance rate of cefepime against P. aeruginosa was 71%. A 
study by Ghafur et al. [9] reported 53.8 % of Gram negative 
organisms were resistant to cefepime. Other in vitro studies have 
recently been published with similar results [10]. Very recently, 
Chaudhary and Payasi [11] demonstrated that majority of the Gram 
negative strains were resistant to cefepime (55.4-63.3%). 
Resistance to the expanded-spectrum cephalosporins among 
members of Enterobacteriaceae, Pseudomonas spp. and 
Acinetobacter spp. may primarily result from extended spectrum β-
lactamases (ESBLs) production [12, 13]. The incidence of ESBLs is 
observed to vary significantly in different geographical areas 
involving from 73.5 to 66.7% in India [14, 15], 54.7% to 59.2% in 
Iran [16] and 41% in United Arab Emirates [17].  
India has very high rates of ESBLs producing Gram negative 
organisms thereby leaving carbapenems only reliable options. 
However, in recent years, Escherichia coli, Klebsiella pneumoniae, 
Acinetobacter baumannii and Pseudomonas aeruginosa have started 
showing decreased susceptibility towards carbapenems [18].  
The concomitant decreased in efficiency of extended-spectrum 
cephalosporins emphasize the necessity of selection of an 
appropriate empiric treatment of nosocomial infections caused by 
ESBL-producing pathogens. β-Lactam-β-lactamase inhibitor 
combinations may be considered to be potential alternative to 
monotherapy of cephalosporins. Keeping it in mind our study was 
aimed to determine the relative efficiency of cefepime/sulbactam 
when compared to cefepime, cefepime/tazobactam and 
imipenem/cilastatin against ESBL-producing Gram negative 
organisms. 
MATERIALS AND METHODS 
Drugs 
Cefepime plus sulbactam (Supime), cefepime, cefepime+tazobactam 
and imipenem plus cilastatin were used in the study. All the drugs 
were reconstituted in water for injection except Supime which was 
reconstituted in the solvent provided with pack. 
Sample collection 
Different clinical samples such as blood, pus, sputum, urine, fluid 
samples, bile, swab, were collected from 1259 (One thousand two 
hundered and fifty nine) patients suspected of bacterial infection 
from various hospitals between July 2013 to July 2014.  
The collection and processing of the samples were done according to 
a common standard operating procedure (SOP). The ethical 
approval of the study is 14-17. 
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Isolation and identification of pathogens 
All the samples were collected asceptically in sterile containers. Urine 
samples collected in sterile universal container and were directly 
inoculated onto the cystine lactose electrolyte deficient (CLED) 
medium. Other specimens involving pus, sputum, bile and fluid 
samples, collected in sufficient amount and were inoculated on the 
different non-selective and selective culture media as per the standard 
microbiological techniques. Blood samples collected in brain heart 
infusion (BHI) broth in a ratio of 1:5 (blood/broth) were first 
incubated overnight at 37 °C and then subcultured on to the non-
selective and selective culture media. The organisms were identified 
on the basis of colony morphology, Gram staining, motility, and 
biochemical reactions [19]. Following various selective culture media 
were used for isolation of different pathogens i.e. for E. coli eosine 
methylene blue (EMB) agar medium was used, for A. baumannii leeds 
Acinetobacter agar base medium was used, for Klebsiella spp. and H. 
influenzae hicrome Klebsiella selective agar base medium and BD brain 
heart infusion agar with 15% horse blood and bacitracin were used 
respectively, whereas for P. aeruginosa citrimide agar was used 
Screening of isolates for ESBL production 
Screening of isolates for extended-spectrum beta-lactamases 
(ESBLs) production was performed according to the procedures 
recommended by the Clinical and Laboratory Standards Institute 
(CLSI) guidelines [20], using indicator cephalosporins, ceftriaxone 
(30μg), ceftazidime (30μg) and cefotaxime (30μg). Isolates 
exhibiting zone size ≤ 25 with ceftriaxone, ≤ 22 for ceftazidime and 
≤27 with cefotaxime were considered possible ESBLs producer.  
Antibiotic susceptibility testing 
Antimicrobial susceptibility testing was done by the cup-plate agar 
diffusion method; a modification described earlier [21]. Inoculum 
containing 106cfu/ml of test strain was spread with a sterile swab on 
a petri dish containing Mueller-Hinton agar and the plates were 
dried. The cups were made in the agar plate using a sterile cork 
borer (6.5 mm) and the disks were removed. Then, 30 µl of the 
antibiotic preparation was placed in the wells using a micro-pipette 
and allowed to diffuse at room temperature. The plates were 
incubated in the upright position at 37 °C for 18 hours. After 
incubation, the zone of inhibition around the wells was measured in 
mm (millimeter), averaged and the mean values were recorded. 
Sensitivity of isolated organisms against antibiotics were reported 
as sensitive (S) or resistant (R) based on the breakpoints.  
RESULTS AND DISCUSSION 
A total 1259 different clinical samples of urine, blood, pus, sputum, 
bile, swab and fluid samples were collected from patients admitted 
to different hospitals of India and these samples were processed for 
isolation of pathogenic organisms. Out of the samples analyzed, 64.3 
% (810/1259) samples showed the growth of organisms while in 
449 samples showed no growth in the culture medium (table 1). Of 
the 810 organisms, 72.7 % (589/810) were ESBL positive. Among 
the ESBL producing organisms around 32.2 % pathogens were 
obtained from urine followed by blood, swab and sputum samples 
which contributed to 28.5 %, 12.7% and 11.3 % respectively. Pus, 
bile and fluid samples contributed to 8.1 %, 4.0 %, and 3.0 % 
respectively (table 1). 
 
Table 1: Clinical samples used as a source of the pathogenic isolates and their identification of ESBL positive isolates 
Clinical samples Total clinical specimens Samples showing growth  ESBL positive isolates Samples not showing growth  
Urine 327 235 190 92 
Blood 374 223 168 151 
Sputum 150 110 67 40 
Swab 139 109 75 30 
Pus 119 60 48 59 
Bile 104 45 23 59 
Fluid samples 46 28 18 18 
Total 1259 810 589 449 
 
Morphological and biochemical characterization of the ESBL positive 
pathogens revealed the presence of 5 different Gram negative organisms 
in clinical samples. The detailed profile of various organisms is shown in 
fig. 1. The identified bacteria include E. coli (n=255), P. aeruginosa (208), 
Klebsiella spp. (81), A. baumannii (32), and H. influenzae (13), indicating 
E. coli (43.3%) was the most dominant pathogen which is in agreement 
with previous study [22] fig. 2.  
In another study, Shafiyabi et al. [23], demonstrated 39.6% prevalence of 
E. coli. This goes with results that obtained in Tanzania [24]. In our study, 
P. aeruginosa contributed 35.3% to the isolated pool of organisms. A 
study performed by Rit  et al. [25] reported 50.2% prevalence rate of P. 
aeruginosa. Other studies reported 10 to 60 % incidence of P. aeruginosa 
in various clinical samples [26-28].  
The results of the present study showed that the prevalence of 
Klebsiella spp. was 13.7 % which were in accordance with the results 
reported by Kumar and Kalpana [29], where they demonstrated 
prevalence of K. pneumoniae (14.5 %) among clinical isolates.  
However, A. baumannii (5.4 %) contributed less in the present study 
which was in agreement with previous studies [30, 31]. E. coli was 
the most prevalent pathogen contributing 34.0 %, 29.0 %, 10.6 %, 
9.8 %, 9.0 %, 4.6 %, and 3.0 % in urine, blood, sputum, swab, pus, 
bile and fluid samples, respectively. Prevalence of other ESBL 
producing organisms among various specimens is depicted in fig. 3.  
Resistance to antibiotics is a significant problem in the treatment of 
serious nosocomial infections. Antibiotic therapy is often empiric, 
until a specific pathogen and its antibiotic susceptibility is known. 
The third-generation cephalosporins are widely used for empiric 
therapy but their effectiveness has been limited by the increasing 
prevalence of ESBL producing strains of Pseudomonas spp. and 
Enterobacteriaceae that produces mainly β-lactamases [32]. 
 
 
A-Urine; B-Blood; C-Sputum; D-Swab; E-Pus; F-Bile; G-fluid samples 
Fig. 1: Profile of different clinical isolates isolated from various samples 
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Fig. 2: Prevalence of various pathogens 
  
Fig. 3: Prevalence of ESBL positive pathogens 
 
Antibiogram profile for all organisms isolated from various clinical 
samples is presented in fig. 4 and 5. In this study we observed that 
the activity of cefepime was evidently poor as compared to the other 
antibiotics, whereas the susceptibility of cefepime plus sulbactam 
was the highest among all the isolated pathogen. The susceptibility 
of cefepime plus sulbactam against E. coli, P. aeruginosa, K. 
pneumoniae, A. baumannii, and H. influenzae was 89.9%, 84.6%, 
85%, 90.4% and 100%, respectively which was high compared to 
cefepime, cefepime plus tazobactam and imipenem plus clistatin. 
Wahid et al. [33] reported that cefepime plus sulbactam combination 
shows 90.0 % sensitivity for P. aeruginosa, 90.9 % for E. coli and 
100% sensitivity for Klebsiella spp.  
Another study showed that addition of beta lactamase inhibitors 








Fig. 5: Resistance pattern of Gram negative pathogens isolated 
A high rate of resistance to cefepime (58 %-76.7 %) and 
cefepime plus tazobactam (46 %-68.7%) was observed. Khalili et 
al. [35] noted the resistance rate of Gram negative bacilli to 
cefepime 60, 67.9, 37.9 and 50 % in 2007, 2008, 2009 and 2010, 
respectively in Iran. In another study, resistance to cefepime for 
E. coli, Klebsiella and Pseudomonas to cefepime was reported to 
be 65.1, 32.2 and 80 %, respectively [36]. Jazani et al. [37] 
documented 62.4 to 88.4 % burn isolates of P. aeruginosa were 
resistant to cefepime. De Macedo and Santos [38] reported 51.1 
% resistance to cefepime for P. aeruginosa burn isolates. 
Endimiani et al. [39] noticed that approximately 10-35 % of P. 
aeruginosa clinical isolates were resistant to cefepime in North 
America, America and Europe. 
Ghafur et al. [9] reported that addition of tazobactam increased the 
susceptibility of cefepime from 34.4 to 87.9 % in E. coli, from 42.3 to 
81.0 % in Klebsiella spp. from 72.0 to 81.4 % in Pseudomonas spp. 
and from 17.2 to 54.5 % in Acinetobacter spp. Cefepime/tazobactam 
provided a better invitro sensitivity profile when compared to 
cefepime alone. Contrary to this, our data showed 54 to 31.3 % 
susceptibility of cefepime plus tazobactam against various gram 
negative organisms.  
In the present study, incidence of resistance to imipenem plus 
cilastatin was 11.7 %-23.7 % (table 2). Previous studies showed 
imipenem plus cilastatin resistance varied from 48.6 to 59.2 % 
[17, 40]. 
CONCLUSION 
The bacterial susceptibility and profile of all isolates in this study 
have shown that cefepime/sulbactam and imipenem+cilastatin 
remain the most effective drugs against Gram negative pathogens, 
suggesting that use of cefepime/sulbactam over other antibiotics 
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rational use of antimicrobials and strictly adhere to the concept of 
reserve drugs to minimize the misuse of available antimicrobials. In 
addition, regular antimicrobial susceptibility surveillance is 
essential. 
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